All In Biotech

Drug Trial Radar · NCT05650554

Safety and Immunogenicity of Quadrivalent Influenza mRNA Vaccine MRT5413 in Adult Participants18 Years of Age and Older

Safety and Immunogenicity of Quadrivalent Influenza mRNA Vaccine MRT5413 in Adults Aged 18 Years and Older

Last checked: Nov 20, 2026Latest source record: Mar 19, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingRandomized with 682 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

682

Actual

Start

Dec 12, 2022

Primary completion

Apr 2, 2024

Study completion Apr 2, 2024

Sponsor

Lead sponsor
Sanofi Pasteur, a Sanofi CompanySanofi (SNY)
Sponsor type
Industry
First posted
Dec 14, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, investigator, outcomes assessor)
Primary purpose
Prevention
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

The purpose of this study is to evaluate the safety and immunogenicity of a single intramuscular (IM) injection of up to 3 dose levels of Quadrivalent Influenza messenger ribonucleic acid (mRNA) Vaccine MRT5413 compared to an active control (QIVstandard-dose (SD), QIV high-dose (HD) \[adults ≥ 65 years of age only\], or quadrivalent recombinant influenza vaccine (RIV4)) in adults 18 years of age and older.

Conditions

  • Influenza Immunization

Interventions

  • Quadrivalent Influenza mRNA Vaccine MRT5413Biological

    Pharmaceutical Form: Liquid frozen solution in a vial Route of Administration: Intramuscular injection

  • Quadrivalent Recombinant Influenza VaccineBiological

    Pharmaceutical Form: Liquid frozen solution in a vial Route of Administration: Intramuscular injection

  • Quadrivalent Influenza Standard Dose VaccineBiological

    Pharmaceutical Form: Liquid suspension for injection in pre-filled syringe Route of Administration: Intramuscular injection

  • Quadrivalent Influenza High-Dose VaccineBiological

    Pharmaceutical Form: Liquid suspension for injection in pre-filled syringe Route of Administration: Intramuscular injection

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of participants with immediate adverse events (AEs)Time frame: Within 30 minutes after injection
  2. Number of participants with solicited injection site or systemic reactionsTime frame: Up to 7 days after injection
  3. Number of participants with unsolicited AEsTime frame: Up to 28 days after injection
  4. Number of participants with medically attended adverse events (MAAE)sTime frame: Up to 180 days after injection
  5. Number of participants with serious adverse events (SAEs)Time frame: From Day one to Day 366
  6. Number of participants with out-of-range biological test resultsTime frame: Up to 8 days after injection
  7. Individual Hemagglutination inhibition (HAI) titerTime frame: At Day 1 and Day 29
  8. Percentage of participants with detectable antibody HAI titers greater than or equal to (≥) 10 [1/dil]Time frame: At Day 1 and Day 29
  9. Individual HAI titer ratioTime frame: At Day 1 and Day 29
  10. Number of participants archiving HAI seroconversion against AntigensTime frame: At Day 1 and Day 29
  11. Percentage of participants with antibody HAI titers greater than or equal to (≥) 40 [1/dil]Time frame: At Day 29
  12. Percentage of participants with 2-fold and 4-fold rise in HAI titersTime frame: At Day 1 and Day 29

Locations

35 sites in 3 countries. Site status is shown where the registry gives one.

  • Velocity Clinical Research-Chula Vista Site Number : 8400061

    Chula Vista, California

  • Velocity Gardena Site Number : 8400062

    Gardena, California

  • Long Beach Clinical Trials Site Number : 8400052

    Long Beach, California

  • Velocity Clinical Research, North Hollywood Site Number : 8400051

    North Hollywood, California

  • California Research Foundation Site Number : 8400006

    San Diego, California

  • Accel Clinical Research-Deland Clinical Research Unit Site Number : 8400032

    DeLand, Florida

  • Velocity New Smyrna Beach Site Number : 8400063

    Edgewater, Florida

  • SIMEDHealth, LLC Site Number : 8400014

    Gainesville, Florida

  • Indago Research and Health Center Site Number : 8400044

    Hialeah, Florida

  • Cenexel Research Centers of America Site Number : 8400011

    Hollywood, Florida

  • Florida International Research Center Site Number : 8400045

    Miami, Florida

  • Suncoast Research Associates, LLC Site Number : 8400060

    Miami, Florida

  • Florida Pulmonary Research Center Site Number : 8400036

    Winter Park, Florida

  • Meridian Clinical Research Site Number : 8400022

    Savannah, Georgia

  • Velocity Clinical Research Site Number : 8400024

    Meridian, Idaho

  • DM Clinical Research - Chicago Site Number : 8400025

    River Forest, Illinois

  • Brengle Family Medicine Site Number : 8400039

    Indianapolis, Indiana

  • Velocity Clinical Research Lincoln Site Number : 8400049

    Lincoln, Nebraska

  • Meridian Clinical Research Site Number : 8400017

    Norfolk, Nebraska

  • Velocity Clinical Research Site Number : 8400008

    Omaha, Nebraska

  • Rochester Clinical Research. Inc. Site Number : 8400027

    Rochester, New York

  • Velocity Clinical Research Site Number : 8400001

    Cleveland, Ohio

  • Velocity Clinical Research - Providence Site Number : 8400019

    East Greenwich, Rhode Island

  • Coastal Carolina Research Center Site Number : 8400042

    North Charleston, South Carolina

  • ClinSearch Site Number : 8400013

    Chattanooga, Tennessee

  • Elligo Health Research, Inc. Site Number : 8400002

    Austin, Texas

  • DM Clinical Research- Bellaire Site Number : 8400026

    Houston, Texas

  • Clinical Trials of Texas, Inc. - PPDS Site Number : 8400016

    San Antonio, Texas

  • Investigational Site Number : 0360004

    Darlinghurst, New South Wales, Australia

  • Investigational Site Number : 0360005

    Kanwal, New South Wales, Australia

  • Investigational Site Number : 0360003

    Maroubra, New South Wales, Australia

  • Investigational Site Number : 0360001

    Morayfield, Queensland, Australia

  • Investigational Site Number : 0360002

    North Melbourne, Victoria, Australia

  • Investigational Site Number : 6300001

    Barrio Sabana, Puerto Rico

  • Investigational Site Number : 6300002

    San Juan, Puerto Rico

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.